LumiraDx (Nasdaq:LMDX) announced today that it priced an underwritten public offering worth approximately $75.3 million.
The London-based next-generation point-of-care (POC) diagnostics company is offering 43 million common shares at a price to the public of $1.75 per share.
According to a news release, all shares are being offered by LumiraDx, leading to gross proceeds (before deducting underwriting discounts and commissions and other offering expenses) of approximately $75.3 million. The company said it expects the offering to close on July 25, subject to the satisfaction of customary closing conditions.
LumiraDx also granted underwriters a 30-day option to purchase up to an additional 6.45 million common shares at the public offering price.
Participants in the offering include certain of LumiraDx’s existing shareholders, such as Ron Zwanziger, the company’s LumiraDx’s chair and chief executive. Additional participants include …